Bivalirudin (Angiomax)

Benefits

About Bivalirudin (Angiomax)

Bivalirudin (brand name Angiomax) is a synthetic 20-amino-acid peptide that functions as a specific, reversible direct thrombin inhibitor (DTI). Originally derived from hirudin, the naturally occurring anticoagulant found in the saliva of the medicinal leech Hirudo medicinalis, bivalirudin was engineered to retain potent antithrombotic activity while offering a more predictable pharmacokinetic profile. The peptide received FDA approval in 2000 for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI), including those with or at risk of heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS). Unlike heparin, bivalirudin does not bind to platelet factor 4, eliminating the risk of triggering HIT — a potentially life-threatening immune-mediated complication. Bivalirudin exhibits bivalent binding to thrombin, simultaneously engaging both the catalytic active site and the anion-binding exosite-1. This dual-site interaction provides potent inhibition of both circulating (free) and clot-bound (fibrin-bound) thrombin, an advantage over heparin which can only inhibit circulating thrombin. The binding is reversible because thrombin itself slowly cleaves the bivalirudin Arg3-Pro4 peptide bond, gradually restoring thrombin enzymatic function. Landmark clinical trials including HORIZONS-AMI, EUROMAX, BRIGHT, and BRIGHT-4 have established bivalirudin as a key anticoagulation option during primary PCI for ST-elevation myocardial infarction (STEMI). The HORIZONS-AMI trial demonstrated reduced 30-day major bleeding (4.9% vs 8.3%) and lower all-cause mortality (2.1% vs 3.1%) compared to heparin plus glycoprotein IIb/IIIa inhibitors. The BRIGHT-4 trial further showed that bivalirudin with extended post-PCI infusion reduced both bleeding and stent thrombosis compared to heparin monotherapy. With a half-life of approximately 25 minutes and predominant elimination through proteolytic cleavage rather than hepatic or renal metabolism, bivalirudin offers a rapid onset-offset profile that is particularly valuable in the acute interventional cardiology setting where precise anticoagulation control is critical.

Who Should Consider Bivalirudin (Angiomax)

• Patients undergoing percutaneous coronary intervention (PCI)
• Patients with heparin-induced thrombocytopenia (HIT) or HITTS requiring anticoagulation
• STEMI patients undergoing primary PCI
• Patients with acute coronary syndromes requiring catheterization laboratory anticoagulation
• Patients at high bleeding risk who need procedural anticoagulation

How Bivalirudin (Angiomax) Works

Bivalirudin is a 20-amino-acid synthetic peptide that directly and reversibly inhibits thrombin (Factor IIa), the central serine protease of the coagulation cascade. It functions as a bivalent inhibitor, meaning it simultaneously binds to two distinct sites on the thrombin molecule: the catalytic active site and the anion-binding exosite-1 (also called the fibrinogen recognition site). The N-terminal segment of bivalirudin (D-Phe-Pro-Arg-Pro) binds to and blocks the catalytic active site of thrombin, while the C-terminal segment (a hirudin-like dodecapeptide) occupies exosite-1. This dual-site engagement produces more complete thrombin inhibition than active-site-only inhibitors and, critically, allows bivalirudin to inhibit both free (circulating) thrombin and fibrin-bound (clot-associated) thrombin — a key advantage over heparin-antithrombin complexes, which can only neutralize circulating thrombin. The interaction is inherently self-limiting: once bound, thrombin slowly cleaves the bivalirudin peptide at the Arg3-Pro4 bond, ultimately restoring the catalytic function of the enzyme. This proteolytic cleavage is the primary mechanism of bivalirudin clearance, accounting for approximately 80% of elimination, with the remaining 20% cleared renally. The result is a predictable, short-duration anticoagulant effect with a half-life of approximately 25 minutes in patients with normal renal function. By inhibiting thrombin, bivalirudin blocks thrombin-mediated fibrinogen cleavage to fibrin, Factor V and VIII activation, Factor XIII activation (fibrin cross-linking), and thrombin-induced platelet activation via PAR-1 and PAR-4 receptors.

What to Expect

Dosing Protocol

Note: Bivalirudin is an FDA-approved direct thrombin inhibitor administered exclusively in hospital settings during percutaneous coronary intervention (PCI). Dosing is weight-based: a 0.75 mg/kg IV bolus followed by a continuous infusion of 1.75 mg/kg/h for the duration of the procedure. For STEMI patients, the infusion may be extended up to 4 hours post-PCI at 1.75 mg/kg/h to reduce acute stent thrombosis risk. Renal dose adjustment is required: reduce infusion to 1 mg/kg/h for CrCl <30 mL/min, and 0.25 mg/kg/h for dialysis patients. Activated clotting time (ACT) should be checked 5 minutes after the bolus; an additional 0.3 mg/kg bolus may be given if ACT is subtherapeutic. This is not a self-administered peptide — it is used exclusively under direct medical supervision in catheterization laboratories and ICU settings.

How to Inject Bivalirudin (Angiomax)

Bivalirudin is administered exclusively by intravenous injection and infusion in a hospital catheterization laboratory or ICU setting by trained medical professionals. The standard protocol for PCI involves an initial IV bolus of 0.75 mg/kg injected over 3-5 seconds, immediately followed by a continuous IV infusion at 1.75 mg/kg/h for the duration of the procedure. Five minutes after the bolus, an activated clotting time (ACT) should be measured; if ACT is below 225 seconds, a supplemental bolus of 0.3 mg/kg may be administered. For STEMI patients undergoing primary PCI, consider extending the post-procedural infusion at 1.75 mg/kg/h for 2-4 hours to reduce acute stent thrombosis risk. Reconstitute each 250 mg vial with 5 mL of sterile water for injection, then further dilute in 50 mL of D5W or 0.9% sodium chloride for a final concentration of 5 mg/mL. Dose adjustment is required for renal impairment: reduce infusion rate to 1 mg/kg/h for CrCl <30 mL/min, and to 0.25 mg/kg/h for patients on hemodialysis. Monitor ACT throughout the procedure.

Cycling Protocol

Pharmacokinetics

Side Effects

The most clinically significant adverse effect of bivalirudin is bleeding, which occurs in 1.4% to 3.8% of patients as major bleeding events. Common non-bleeding side effects include hypotension, back pain (occurring in up to 42% of patients in clinical trials, often related to catheterization positioning), nausea, headache, and injection site pain. Serious but less common adverse reactions include cardiac tamponade, pulmonary hemorrhage, retroperitoneal bleeding, intracranial hemorrhage, and cardiogenic shock. Post-marketing surveillance has identified rare cases of anaphylaxis and fatal hemorrhage. An increased risk of acute stent thrombosis (within 24 hours) was observed in early trials when bivalirudin infusion was stopped immediately after PCI; this risk is mitigated by extending the infusion for 2-4 hours post-procedure. Thrombocytopenia has been reported rarely. INR elevation may occur when transitioning to warfarin therapy.

Contraindications

Drug Interactions

Storage & Stability

Molecular Profile

Related Peptides

Icatibant (Firazyr)

Immune

Ziconotide (Prialt)

Healing & Recovery

Octreotide (Sandostatin)

Metabolic

References

1. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary PCI: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trialsClinical Trial
2. Bivalirudin started during emergency transport for primary PCI (EUROMAX trial)Clinical Trial
3. Bivalirudin: a direct thrombin inhibitor — comprehensive pharmacology reviewReview
4. ANGIOMAX (bivalirudin) for Injection — FDA Prescribing Information (2019)FDA Label
5. Outcome of the HORIZONS-AMI trial: bivalirudin enhances long-term survival in STEMI patients undergoing angioplastyClinical Trial